Publications by authors named "Josef Straub"

Claim this Profile
T
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Hiroshi Sakai, Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Tomohiro Sakamoto, Josef Straub

Jpn J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Thomas Decaens, Carlo Barone, Eric Assenat, Martin Wermke, Angelica Fasolo, Josef Straub

Br J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Thomas Decaens, Carlo Barone, Eric Assenat, Martin Wermke, Angelica Fasolo, Josef Straub

Br J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Baek-Yeol Ryoo, Ann-Li Cheng, Zhenggang Ren, Tae-You Kim, Hongming Pan, Josef Straub

Br J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Yi-Long Wu, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Josef Straub

Lancet Respir Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Josef Straub

N Engl J Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
Monika E Hegi, Els Genbrugge, Thierry Gorlia, Roger Stupp, Mark R Gilbert, Josef Straub

Clin Cancer Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Maha Hussain, Sylvestre Le Moulec, Claude Gimmi, Rolf Bruns, Josef Straub

Clin Cancer Res· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Michael Weller, Louis Burt Nabors, Thierry Gorlia, Henning Leske, Elisabeth Rushing, Josef Straub

Oncotarget· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
Isabelle Renard, Steven Joniau, Ben van Cleynenbreugel, Catherine Collette, Christophe Naômé, Josef Straub

Eur Urol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.
Ilse Vlassenbroeck, Stéphane Califice, Annie-Claire Diserens, Eugenia Migliavacca, Josef Straub

J Mol Diagn· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of metallothionein by zinc protects from daunorubicin toxicity in rats.
Mamdouh M Ali, Eva Frei, Josef Straub, Andrea Breuer, Manfred Wiessler

Toxicology· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin D1 is not an essential target of beta-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice.
Jenny Wilding, Josef Straub, Julie Bee, Michael Churchman, Walter Bodmer

Cancer Res· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis